Medscape Hematology-Oncology Headlines 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.Which Patients Benefit From Endocrine Therapy Beyond 5 Yrs? Which Patients Benefit From Endocrine Therapy Beyond 5 Yrs?
Japanese investigators identified a group of patients with breast cancer who demonstrated improved long-term outcomes on endocrine therapy beyond the usual 5 years.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 12, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news
Periocular Melanoma Still Rare, But May Be Increasing Periocular Melanoma Still Rare, But May Be Increasing
Pain and vision loss are late symptoms of periocular melanoma, and there are amelanotic variants.MDedge News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 9, 2024 Category: Cancer & Oncology Tags: Dermatology Source Type: news
Study Shows Disparities in Diagnosing Across Skin Tones Study Shows Disparities in Diagnosing Across Skin Tones
Across all images, diseases in darker skin types were diagnosed less accurately than diseases in lighter skin types, including when decision support from a deep learning system was introduced.MDedge News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 9, 2024 Category: Cancer & Oncology Tags: Dermatology Source Type: news
Belantamab Mafodotin Tops Daratumumab in Multiple Myeloma Belantamab Mafodotin Tops Daratumumab in Multiple Myeloma
The phase 3 study findings supported belantamab mafodotin as a potential new standard of care in the second line or later among patients with released/refractory multiple myeloma.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 9, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news
Is Consolidation Osimertinib Superior in EGFR-Mutated NSCLC? Is Consolidation Osimertinib Superior in EGFR-Mutated NSCLC?
A retrospective study showed consolidated osimertinib after chemoradiation prolonged progression-free survival in patients with EGFR-mutated, stage III NSCLC compared with durvalumab or observation.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 8, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news
Screening and Treatment Reduce Breast Cancer Mortality Screening and Treatment Reduce Breast Cancer Mortality
Simulation models indicate that breast cancer screening and treatment were associated with a 58% reduction in mortality, based on data collected between 1975 and 2019.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 8, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news
Immune-Related AEs Predict Outcomes in Advanced GU Cancers Immune-Related AEs Predict Outcomes in Advanced GU Cancers
Patients with advanced GU cancers who had immune-related AEs from immunotherapy had better overall survival — a phenomenon also reported for other cancer types.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 8, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news
ASCO Insights: Impacts on Lung Cancer Care ASCO Insights: Impacts on Lung Cancer Care
Dr Mark Kris discusses conversations from ASCO 2023 that may affect the care of patients with lung cancers.Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 7, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news
US FDA Puts Hold on Gilead's Blood Cancer Therapy Trials US FDA Puts Hold on Gilead's Blood Cancer Therapy Trials
Gilead Sciences said on Wednesday the U.S. Food and Drug Administration had put a hold on trials testing the company ' s blood cancer drug following increased risk of patient...Reuters Health Information (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 7, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news
Regrowth Predicts Metastasis in Rectal Cancer Watch and Wait Regrowth Predicts Metastasis in Rectal Cancer Watch and Wait
A large retrospective study addressed the risk of opting for " watch and wait " in rectal cancer.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 7, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news
SBRT Safe, Effective for Patients With Nonspine Bone Mets SBRT Safe, Effective for Patients With Nonspine Bone Mets
Stereotactic body radiation for nonspine bone metastases is associated with a low rate of local failures, fractures, and acute toxicity, according to a large meta-analytic review.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 6, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news
Machine Learning Helps Predict HCC Risk in MASLD Machine Learning Helps Predict HCC Risk in MASLD
A machine learning model can help estimate the risk for hepatocellular carcinoma in patients with metabolic dysfunction-associated steatotic liver disease.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 6, 2024 Category: Cancer & Oncology Tags: Gastroenterology Source Type: news
Durvalumab Plus Bevacizumab Improves TACE Outcomes in HCC Durvalumab Plus Bevacizumab Improves TACE Outcomes in HCC
A new study showed improved progression-free survival when systemic therapy is added to TACE for HCC. Overall survival outcomes are pending.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 6, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news
Does Eliminating Alcohol Intake Lower Cancer Risk? Does Eliminating Alcohol Intake Lower Cancer Risk?
When it comes to the link, a new report from WHO revealed limited or inadequate evidence to suggest consuming less alcohol or stopping altogether reduced the risk for most cancers.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 6, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news
DUO-E: PARP Inhibitor Combination Improves Survival DUO-E: PARP Inhibitor Combination Improves Survival
Dr Maurie Markman discusses results from the DUO-E trial.Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 5, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news
